Centiva Capital LP boosted its holdings in Novartis AG (NYSE:NVS - Free Report) by 126.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,119 shares of the company's stock after acquiring an additional 2,856 shares during the period. Centiva Capital LP's holdings in Novartis were worth $498,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in the business. JPMorgan Chase & Co. increased its holdings in shares of Novartis by 35.6% in the fourth quarter. JPMorgan Chase & Co. now owns 423,142 shares of the company's stock valued at $41,176,000 after buying an additional 111,066 shares in the last quarter. Foundations Investment Advisors LLC grew its holdings in shares of Novartis by 26.9% during the 4th quarter. Foundations Investment Advisors LLC now owns 89,074 shares of the company's stock valued at $8,668,000 after acquiring an additional 18,894 shares in the last quarter. Chicago Partners Investment Group LLC purchased a new position in shares of Novartis during the 4th quarter valued at $239,000. Agate Pass Investment Management LLC acquired a new stake in shares of Novartis in the 4th quarter valued at $702,000. Finally, Flywheel Private Wealth LLC acquired a new stake in shares of Novartis in the 4th quarter valued at $272,000. Institutional investors own 13.12% of the company's stock.
Analyst Ratings Changes
A number of research analysts have recently commented on the stock. BNP Paribas raised shares of Novartis to a "strong-buy" rating in a research report on Tuesday, April 15th. Deutsche Bank Aktiengesellschaft raised shares of Novartis from a "hold" rating to a "buy" rating in a research note on Tuesday, February 4th. Barclays restated an "underweight" rating on shares of Novartis in a report on Monday, February 3rd. Morgan Stanley started coverage on shares of Novartis in a report on Wednesday, February 12th. They issued an "underweight" rating on the stock. Finally, StockNews.com upgraded shares of Novartis from a "buy" rating to a "strong-buy" rating in a report on Saturday, February 8th. Three analysts have rated the stock with a sell rating, six have given a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Novartis currently has an average rating of "Hold" and a consensus target price of $123.38.
Get Our Latest Research Report on NVS
Novartis Stock Performance
Shares of NVS traded down $1.65 during midday trading on Wednesday, reaching $105.18. The stock had a trading volume of 2,054,547 shares, compared to its average volume of 1,577,151. The firm has a 50 day simple moving average of $110.07 and a 200-day simple moving average of $105.81. Novartis AG has a one year low of $96.06 and a one year high of $120.92. The firm has a market cap of $222.18 billion, a PE ratio of 17.89, a P/E/G ratio of 1.70 and a beta of 0.60. The company has a current ratio of 1.04, a quick ratio of 0.84 and a debt-to-equity ratio of 0.48.
Novartis (NYSE:NVS - Get Free Report) last announced its earnings results on Tuesday, April 29th. The company reported $2.28 EPS for the quarter, topping the consensus estimate of $2.12 by $0.16. The business had revenue of $13.23 billion during the quarter, compared to the consensus estimate of $12.92 billion. Novartis had a net margin of 23.56% and a return on equity of 37.24%. Novartis's revenue was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.80 EPS. As a group, sell-side analysts anticipate that Novartis AG will post 8.45 EPS for the current year.
Novartis Announces Dividend
The company also recently announced a dividend, which was paid on Wednesday, March 12th. Stockholders of record on Wednesday, March 12th were given a $3.8695 dividend. The ex-dividend date of this dividend was Wednesday, March 12th. Novartis's payout ratio is presently 40.47%.
About Novartis
(
Free Report)
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Read More
Before you consider Novartis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.
While Novartis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
